In today’s Pharmaceutical Executive Daily, a new a is expected to evolve in 2026, the FDA rejects AstraZeneca’s application ...

Discover how a newly developed platform technology from The University of North Carolina at Chapel Hill can enhance RNAi ...

Explore RNA interference methods, comparing siRNA and shRNA for gene knockdown, their mechanisms, advantages, and implications for molecular biology research.

In Regents of the University of California v. Broad Institute, Inc., the Federal Circuit addressed the issue of conception and reduction to ...

Partnership launched under MTEA to evaluate the potential of Vect-Horus technology to deliver siRNAs into the CNSAssessment ...

Some scientists who argue for deregulation deny outdoor gene editing is possible. But patents and the scientific literature tell a very different story. Report: Claire Robinson ...

Arbutus Biotech (ABUS) heads to a key March Moderna LNP patent trial as imdusiran HBV milestones drive value—get the latest ...

Belite Bio (BLTE) stock outlook: tinlarebant clinical data, 2026 filings, key FDA/EU risks, and $165/share valuation. See if ...

Few companies stand better poised than Beam Therapeutics to reap the first fruits of the FDA’s promised flexibility toward cell and gene therapies. | Riding a regulatory win for its base editing ...

Pill versions of the successful GLP1 drugs from Novo Nordisk and Eli Lilly will likely be on the market in 2026’s first half.

At the invitation of the Hon'ble Minister of Petroleum and Natural Gas of India, H.E. Shri Hardeep Singh Puri, the Hon'ble Minister of Energy and Natural Resources of Canada, H.E. Timothy Hodgson, ...

The global demand on agri-food systems continues to grow, necessitating innovative strategies for increasing agricultural ...